抗血管内皮生长因子融合蛋白在眼科的应用

Application of anti-vascular endothelial growth factor fusion protein in ophthalmology

抗血管内皮生长因子(vascular endothelial growth factor,VEGF)融合蛋白是由VEGF受体与免疫球蛋白G的Fc段结合形成,可与VEGF受体竞争性结合VEGF,进而阻止VEGF受体激活。抗VEGF融合蛋白对VEGF的结合力远高于单克隆类抗VEGF药物,作为高亲和力的抗VEGF药物广泛应用于治疗VEGF生成、释放、激活异常增多的疾病。目前眼科主要用于减少VEGF生成以消退或预防各类新生血管以及血管病变相关性黄斑水肿的治疗。抗VEGF融合蛋白类药物出现晚于单克隆类,可用于治疗单克隆类抗VEGF药物治疗不佳的病例。同时抗VEGF类药物间更换应用治疗效果优于单一药物应用。抗肿瘤治疗也是抗VEGF融合蛋白药物的潜在应用领域。根据对抗VEGF融合蛋白类药物作用因子及近视形成相关因子表达的研究发现,抗VEGF融合蛋白类药物可能对近视形成产生抑制作用。

Anti-vascular endothelial growth factor(VEGF)fusion protein consisting of VEGF receptor and Fc segment of human IgG,which can be competitive with VEGF receptor in combination with VEGF,thereby VEGF receptor will be prevented from being activated.As the binding capacity of anti-VEGF fusion protein to VEGF is much higher than that of monoclonal anti-VEGF drugs,the high-affinity anti-VEGF drugs has been widely applied in the treatment of diseases abnormally caused by generation,releasing and activation of VEGF.At present,it is mainly used to reduce VEGF production to subside or prevent neovascularization and treatment of macular edema associated with various vascular diseases.Since anti-VEGF fusion protein appeared later than monoclonal drugs,most studies have found that anti-VEGF fusion protein can be used to treat diseases poorly treated by monoclonal drugs.At the same time,it has also been reported that the therapeutic effect of anti-VEGF drugs replacement is better than that of single drug.Anti-tumor therapy is also a potential field for anti-VEGF fusion protein drugs.According to the research on the expression of anti-VEGF fusion protein drugs acting factor and related factors of myopia formation,they may have inhibitory effect on myopia formation.